CALGARY,
AB and MOUNTAIN VIEW,
Calif., June 6, 2022 /PRNewswire/ - Willow
Biosciences Inc. ("Willow" or the "Company")
(TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company
focused on revolutionizing industrial manufacturing of pure,
consistent and sustainable ingredients along with Inscripta®, a
global leader in automated, CRISPR-based gene editing technology,
announced today that Willow has incorporated the Onyx Genome
Engineering Platform into its strain engineering workflows.
Having previously been a part of Inscripta's early access
program, Willow has a deep appreciation for the value that
automated, parallel genome editing capability brings, especially to
a lean biotech company. The integrated and intuitive interface of
the benchtop Onyx instrument uses best-in-class gene editing
technology, enabling scientists to rapidly perform multiplexed,
whole genome CRISPR edits at the push of a button.
The Onyx platform will further accelerate Willow's genetic
editing capabilities and throughput and positively impact timelines
for the commercial development of its FutureGrown™ molecules
and subsequent reduction in time to market. Incorporation of the
Onyx platform into Willow's proven workflow will enable its team to
engineer strains more rapidly, giving researchers back invaluable
time to focus on intelligent library design and data analysis.
"Technology advancements such as next generation sequencing have
enabled researchers to read genetic information at incredible speed
and depth. Inscripta's technology now enables researchers to write
genetic information with the same speed and with unparalleled
precision, a combination that promises endless possibilities.
Willow is thrilled to seamlessly integrate Inscripta's automated,
high-throughput gene editing platform to shorten our development
cycles and empower our scientists to effectively harness the
tremendous potential of the entire genome" said Dr. Trish Choudhary, Vice President of Research
& Development at Willow Biosciences.
"The future of the synthetic biology economy is dependent on
both large and small companies innovating under increasing pressure
to deliver better products, faster, and often with less resources.
Willow is a great example of how a lean, yet highly innovative
organization can rapidly integrate and utilize the Onyx platform,"
said Dr. Nandini Krishnamurthy, Vice
President of Microbial Business Unit at Inscripta. "We are looking
forward to working with the team at Willow to further increase
their strain performance while shortening development
timelines."
About Willow Biosciences
Inc.
Willow develops and produces high-purity ingredients for the
personal care, food and beverage, and pharmaceutical markets.
Willow's FutureGrownÔ biotechnology platform allows
large-scale production with sustainability at its core. Willow's
R&D team has a proven track record of developing and
commercializing bio-based manufacturing processes and products to
benefit our B2B partners and their customers.
For further information, please visit
www.willowbio.com.
About Inscripta
Inscripta® is a life science technology company enabling
scientists to solve some of today's most pressing challenges with
the first benchtop system for genome editing. The company's
automated Onyx® platform, consisting of an instrument, consumables,
assays, and software, makes CRISPR-based genome engineering
accessible to any research lab. Inscripta supports its customers
around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark.
To learn more, visit Inscripta.com
and follow @InscriptaInc. Or
contact
Michael B.
Gonzales
Vice President,
Marketing
michael.gonzales@inscripta.com
415.308.6467
Forward-Looking
Statements
This news release may include forward-looking statements
including opinions, assumptions, estimates and the Company's
assessment of future plans and operations, and, more particularly,
statements concerning: Willow's ability to expand genetic editing
capabilities and throughput and positively impact timelines for the
commercial development of its FutureGrown™ molecules; and the
business plan of the Company. When used in this news release, the
words "will," "anticipate," "believe," "estimate," "expect,"
"intent," "may," "project," "should," and similar expressions are
intended to be among the statements that identify forward-looking
statements. The forward-looking statements are founded on the basis
of expectations and assumptions made by the Company which include,
but are not limited to: the success of Willow's strategic
partnerships, including the development of future strategic
partnerships; the financial strength of the Company; the ability of
the Company to fund its business plan using cash on hand and
existing resources; the market for Willow's products; the ability
of the Company to obtain and retain applicable licences; the
ability of the Company to obtain suitable manufacturing partners
and other strategic relationships; and the successful
implementation of Willow's commercialization and production
strategy, generally. Forward-looking statements are subject to a
wide range of risks and uncertainties, and although the Company
believes that the expectations represented by such forward-looking
statements are reasonable, there can be no assurance that such
expectations will be realized. Any number of important factors
could cause actual results to differ materially from those in the
forward-looking statements including, but not limited to, risks
associated with: the biotechnology industry in general; the success
of the Company's research and development strategies; infringement
on intellectual property; failure to benefit from partnerships or
successfully integrate acquisitions; actions and initiatives of
federal and provincial governments and changes to government
policies and the execution and impact of these actions, initiatives
and policies; competition from other industry participants; adverse
U.S., Canadian and global economic conditions; adverse global
events and public-health crises, including the current COVID-19
outbreak; failure to comply with certain regulations; departure of
key management personnel or inability to attract and retain talent;
and other factors more fully described from time to time in the
reports and filings made by the Company with securities regulatory
authorities. Please refer to the Company's most recent annual
information form and management's discussion and analysis for
additional risk factors relating to Willow, which can be accessed
either on Willow's website at www.willowbio.com or under the
Company's profile on www.sedar.com.
Any financial outlook and future-oriented financial information
contained in this document regarding prospective financial
performance, financial position, cash balances or revenue is based
on assumptions about future events, including economic conditions
and proposed courses of action based on management's assessment of
the relevant information that is currently available. Projected
operational information contains forward-looking information and is
based on a number of material assumptions and factors, as are set
out above. These projections may also be considered to contain
future-oriented financial information or a financial outlook. The
actual results of the Company's operations for any period will
likely vary from the amounts set forth in these projections and
such variations may be material. Actual results will vary from
projected results. Readers are cautioned that any such financial
outlook and future-oriented financial information contained herein
should not be used for purposes other than those for which it is
disclosed herein.
The forward-looking statements contained in this news release
are made as of the date hereof and the Company does not undertake
any obligation to update publicly or to revise any of the included
forward-looking statements, except as required by applicable law.
The forward-looking statements contained herein are expressly
qualified by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-incorporates-inscriptas-onyx-platform-to-expand-strain-engineering-capabilities-and-throughput-301561340.html
SOURCE Willow Biosciences Inc.